

Oliver Van Oekelen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5183564/publications.pdf>

Version: 2024-02-01

15
papers

2,452
citations

1307594

7
h-index

1058476

14
g-index

18
all docs

18
docs citations

18
times ranked

6428
citing authors

#	ARTICLE	IF	CITATIONS
1	An inflammatory cytokine signature predicts COVID-19 severity and survival. <i>Nature Medicine</i> , 2020, 26, 1636-1643.	30.7	1,860
2	Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. <i>Cancer Cell</i> , 2021, 39, 1028-1030.	16.8	176
3	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. <i>Journal of Hematology and Oncology</i> , 2020, 13, 94.	17.0	107
4	Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. <i>Nature Medicine</i> , 2021, 27, 2099-2103.	30.7	92
5	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. <i>Cancer Cell</i> , 2021, 39, 1442-1444.	16.8	62
6	Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients. <i>Cancer Cell</i> , 2022, 40, 441-443.	16.8	29
7	Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 5895-5902.	7.0	25
8	A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2208-2215.	1.3	7
9	Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T. <i>Blood</i> , 2021, 138, 2704-2704.	1.4	6
10	Multi-Omics Profiling of the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1361, 283-326.	1.6	6
11	Single-Cell Profiling Reveals Contribution of Tumor Extrinsic and Intrinsic Factors to BCMA-Targeted CAR-T Cell Efficacy in Multiple Myeloma. <i>Blood</i> , 2021, 138, 326-326.	1.4	5
12	Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Ibrandomide-Treated Myeloma Patients. <i>Blood</i> , 2021, 138, 730-730.	1.4	4
13	Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Ibrandomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients. <i>Blood</i> , 2019, 134, 1775-1775.	1.4	3
14	Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs). <i>Blood</i> , 2021, 138, 821-821.	1.4	2
15	Mass cytometry reveals increase in marrow resident monocytes associated with response to daratumumab and pomalidomide. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e99-e100.	0.4	0